Dec 9 (Reuters) - Alexza Pharmaceuticals Inc said AZ-004, its drug to treat acute agitation, met the main goal of a late-stage trial and that it expects to file for marketing approval in early 2010.

Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by ...

Emergency departments (EDs) worldwide are frequently tasked with the management of patients exhibiting acute agitation and delirium. These conditions, which may arise from underlying psychiatric ...

NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its ...

Credit: Getty Images Prioritizing nonpharmacologic strategies, enhancing staff training, and distinguishing Delirium Superimposed on Dementia (DSD) are vital to improving outcomes for hospitalized ...

NEW HAVEN, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

Good morning, everyone, and thank you for joining us today. I would like to start by welcoming our distinguished participants. We are grateful to each of you for bringing your deep experience in the ...

A recent review article provides critical insights into the management of acute agitation in reproductive-age females and during pregnancy within the emergency departments (EDs). The study emphasizes ...

First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Received FDA feedback on protocol for TRANQUILITY ...